EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic burden of pulmonary arterial hypertension in Switzerland

Yuki Tomonaga iD, Mona Lichtblau, Silvia Ulrich, Sabina A Guler, Patrick Yerly iD, Benoît Lechartier, Jean-Marc Fellrath, Anne Bergeron, Louise Bondeelle, Silviu-Mihail Chirila, Andrea Favre-Bulle, Sandro Stoffel und 1 weitere

PLOS One · 28.04.2026 · 21 (4) · e0348190

DOI: 10.1371/journal.pone.0348190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 28.04.2026. Verfasst von Yuki Tomonaga und 12 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Cost of Illness, Health Care Costs, Pulmonary Arterial Hypertension. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD, Luzern, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pulmonary arterial hypertension (PAH) is a rare, progressive condition associated with high morbidity and healthcare resource utilization. This study aimed to estimate the annual direct and indirect costs of PAH in Switzerland, from a societal perspective. Materials and methods A cross-sectional cost-of-illness study was conducted across six Swiss PAH centres between April and December 2024. Adult patients with confirmed PAH (World Health Organization [WHO] Group 1) were invited to complete a standardized questionnaire on work productivity losses, informal care, and healthcare utilization outside the enrolling centre. Clinical data on hospitalizations, outpatient visits, diagnostics, and treatments at the enrolling centre were extracted from medical records. Disease-specific costs were calculated by multiplying resource use and work losses by Swiss-specific unit costs and extrapolated to one year. Estimates were stratified by WHO functional class (WHO-FC) and ESC/ERS 2022 risk strata.

Results

Among 124 participants aged between 18 and 89 years, the mean disease-specific total annual cost per patient was €138,958. Direct healthcare costs represented 78.5% of this amount (€109,114), driven primarily by pharmacological treatment (65% of total costs). Indirect costs amounted to 21.5% (€29,844). Costs increased with disease severity, ranging from €81,957 in WHO-FC 1 to €166,569 in WHO-FC 4, and from €130,970 in ESC/ERS low risk to €291,728 in ESC/ERS high risk. The total national burden was estimated at €48.5 million annually.

Conclusions

PAH imposes a substantial economic burden in Switzerland, largely due to treatment costs and productivity losses. These findings highlight the need for strategies to reduce disease progression and associated societal costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost of IllnessHealth Care CostsPulmonary Arterial HypertensionHumansSwitzerlandFemaleMaleMiddle AgedAdultAgedCross-Sectional StudiesAdolescentAged, 80 and overYoung AdultHospitalization

Autor:innen und Institutionen

  • Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.
  • Department of Pulmonary Medicine, University Hospital of Zurich (USZ), Zurich, Switzerland.
  • Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Cardiology, Lausanne University Hospital (CHUV), Switzerland.
  • Department of Respiratory Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Service of Pulmonary Medicine, Réseau Hospitalier Neuchâtelois (RHNe), Neuchâtel, Switzerland.

ORCID-Profile: Yuki Tomonaga, Patrick Yerly, Matthias Schwenkglenks

Förderung

  • MSD, Luzern, Switzerland

Zitieren

APA

Tomonaga, Y., Lichtblau, M., Ulrich, S., Guler, S. A., Yerly, P., Lechartier, B., Fellrath, J. M., Bergeron, A., Bondeelle, L., Chirila, S. M., Favre-Bulle, A., Stoffel, S., & Schwenkglenks, M. (2026). Economic burden of pulmonary arterial hypertension in Switzerland. PLOS One, 21(4), e0348190. https://doi.org/10.1371/journal.pone.0348190

Vancouver

Tomonaga Y, Lichtblau M, Ulrich S, Guler SA, Yerly P, Lechartier B, et al. Economic burden of pulmonary arterial hypertension in Switzerland. PLOS One. 2026;21(4):e0348190. doi:10.1371/journal.pone.0348190

BibTeX
@article{Tomonaga2026,
  author = {Tomonaga, Yuki and Lichtblau, Mona and Ulrich, Silvia and Guler, Sabina A and Yerly, Patrick and Lechartier, Benoît and Fellrath, Jean-Marc and Bergeron, Anne and Bondeelle, Louise and Chirila, Silviu-Mihail and Favre-Bulle, Andrea and Stoffel, Sandro and Schwenkglenks, Matthias},
  title = {Economic burden of pulmonary arterial hypertension in Switzerland},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {4},
  pages = {e0348190},
  doi = {10.1371/journal.pone.0348190}
}
Kostenlos starten →